CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zafgen, Inc., a private venture-backed biopharmaceutical company focused on developing novel obesity therapeutics, today announced that Randy J. Seeley, Ph.D., professor of psychiatry and associate director for the Metabolic Disease Institute at the University of Cincinnati College of Medicine, and a member of Zafgen’s scientific advisory board, will deliver a keynote lecture during the American Diabetes Association’s (ADA) 69th Annual Scientific Sessions, being held June 5-9 in New Orleans. Dr. Seeley’s lecture will highlight the nature and function of adipose (fat) tissue as a significant determinant of obesity, and a groundbreaking approach to developing novel obesity therapeutics that directly targets adipose vasculature to shrink fat cells and help the body sustain a lean, healthy state.
